{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:32:29Z","timestamp":1787027549142,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The most efficacious antimicrobial therapy to aid in the successful elimination of resistant S. aureus infections is unknown. In this study, we evaluated varying phenotypes of S. aureus against dalbavancin (DAL), vancomycin (VAN), and daptomycin (DAP) alone and in combination with cefazolin (CFZ). The objective of this study was to observe whether there was a therapeutic improvement in adding a beta-lactam to a glycopeptide, lipopeptide, or a lipoglycopeptide. We completed a series of in vitro tests including minimum inhibitory concentration testing (MIC) of the antimicrobials in combination, time-kill analysis (TKA), and a 168 h (7-day) one-compartment pharmacokinetic\/pharmacodynamic (PK\/PD) model on two daptomycin non-susceptible (DNS), vancomycin intermediate S. aureus strains (VISA), D712 and 6913. Results from our MIC testing demonstrated a minimum 2-fold and a maximum 32-fold reduction in MIC values for DAL, VAN, and DAP in combination with CFZ, in contrast to either agent used alone. The TKAs completed on four strains paralleled the enhanced activity demonstrated via the combination MICs. In the one-compartment PK\/PD models, the combination of DAP plus CFZ or VAN plus CFZ resulted in a significant (p &lt; 0.001) improvement in bactericidal activity and overall reduction in CFU\/ml over the 7-day period. While the addition of CFZ to DAL improved time to bactericidal activity, DAL alone demonstrated equal and more sustained overall activity compared to all other treatments. The use of DAL alone, with or without CFZ and the combinations of VAN or DAP with CFZ appear to result in increased bactericidal activity against various recalcitrant S. aureus phenotypes.<\/jats:p>","DOI":"10.3390\/antibiotics9100696","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T08:59:22Z","timestamp":1602665962000},"page":"696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic\/Pharmacodynamic Model"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-6408","authenticated-orcid":false,"given":"Jacinda C.","family":"Abdul-Mutakabbir","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Stamper","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip T.","family":"Maassen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Lev","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA"},{"name":"School of Medicine, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"ref_1","first-page":"269","article-title":"Vancomycin Resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.15.3.430-438.2002","article-title":"Vancomycin resistance in staphylococci","volume":"15","author":"Srinivasan","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00223-11","article-title":"In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"55","author":"Mishra","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40121-014-0023-0","article-title":"Observation of \u201cseesaw effect\u201d with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains","volume":"3","author":"Barber","year":"2014","journal-title":"Infect. Dis. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ijid.2010.05.009","article-title":"Methicillin-resistant Staphylococcus aureus: Related infections and antibiotic resistance","volume":"14","author":"Stefani","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_9","unstructured":"Dalbavancin (2006). Drugs and Lactation Database (LactMed), Bethesda."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0213-005X(17)30031-9","article-title":"Dalbavancin: Pharmacokinetic and pharmacodynamic parameters","volume":"35","author":"Azanza","year":"2017","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(89)90076-7","article-title":"World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus","volume":"1","author":"Maple","year":"1989","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.05473-11","article-title":"In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus","volume":"56","author":"Hagihara","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2018.03.020","article-title":"Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus","volume":"91","author":"Singh","year":"2018","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: Role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1128\/AAC.00594-13","article-title":"beta-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus","volume":"57","author":"Berti","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.50.2.428-438.2006","article-title":"Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/jb.179.8.2557-2566.1997","article-title":"Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus","volume":"179","author":"Sieradzki","year":"1997","journal-title":"J. Bacteriol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/39.suppl_1.47","article-title":"Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics","volume":"39","author":"Sieradzki","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1198-743X.2004.00856.x","article-title":"False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods","volume":"10","author":"Goldstein","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tran, K.N., and Rybak, M.J. (2018). beta-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00157-18"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","article-title":"Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods","volume":"47","author":"Liu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/AAC.01185-12","article-title":"Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations","volume":"56","author":"Steed","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","unstructured":"Clinical and Laboratory Standards Institute (2019, September 09). M100-S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Eigth Informational Supplement. Available online: https:\/\/clsi.org\/media\/1930\/m100ed28."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kebriaei, R., Rice, S.A., Stamper, K.C., and Rybak, M.J. (2019). Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic\/Pharmacokinetic Model. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01743-18"},{"key":"ref_33","unstructured":"Interscience (2018). easySpiral: Technical Specifications, Interscience."},{"key":"ref_34","unstructured":"Food and Drug Administration (2014). Dalbavancin: Package Insert Administration."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/dkn439","article-title":"Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"63","author":"Leonard","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1128\/AAC.05033-11","article-title":"Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery","volume":"55","author":"Douglas","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jchromb.2008.09.019","article-title":"Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma","volume":"875","author":"Kielstein","year":"2008","journal-title":"J. Chromatogr. B Analyt Technol. Biomed Life Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/10\/696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:20:55Z","timestamp":1760178055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/10\/696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["antibiotics9100696"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9100696","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]}}}